## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of the Claims:

- (currently amended) A method of treatment for a mammal, with advanced or large tumor burdens, comprising the administration to said mammal of a T-cell co-stimulatory cell adhesion molecule (CAM) in conjunction with a tumor growth-restricting agent, either of which alone would be ineffective in eradicating treating an advanced or large tumor burden, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.
- (currently amended) A method of treating a patient with cancer which comprises
  the step of administering to said patient a CAM and a tumor growth-restricting agent in amounts
  which are together effective to eradicate treat any advanced or large tumors present, wherein said
  CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.
- 3. (currently amended) A method of potentiating the activity of a CAM against tumors present in a patient suffering from cancer which comprises the step of administering to said patient treated with said CAM an amount of a tumor growth-restricting agent, which is effective, in combination with said CAM to eradicate treat any advanced or large tumors present in said patient, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.
- 4. (currently amended) A method of potentiating the activity of a tumor growth restricting agent against tumors present in a patent suffering from cancer which comprises the step of pre-administering to a patient to be treated with said tumor growth-restricting agent an amount of CAM which, upon subsequent administration of said tumor growth restricting agent, acts in combination with said tumor growth restricting agent to eradicate treat an advanced or large tumors present, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.
  - 5-9. (canceled).

- (withdrawn) A method as claimed in claim 1, wherein the tumor growthrestricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
- (withdrawn) A method as claimed in claim 10, wherein the wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.
- (previously presented) A method as claimed in claim 1, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.
- (previously presented) A method as claimed in claim 12, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.
- (original) A method as claimed in claim 1, wherein the method further includes the administration of an additional tumor growth-restricting agent.
- (withdrawn) A method as claimed in claim 14, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).
  - 16-17. (canceled).
- (withdrawn) A method as claimed in claim 2, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
- (withdrawn) A method as claimed in claim 18, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.
- (previously presented) A method as claimed in claim 2, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.
- 21. (previously presented) A method as claimed in claim 20, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.

- (original) A method as claimed in claim 2, wherein the method further includes the administration of an additional tumor growth-restricting agent.
- 23. (withdrawn) A method as claimed in claim 22, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).
  - 24-25. (canceled).
- 26. (withdrawn) A method as claimed in claim 3, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
- 27. (withdrawn) A method as claimed in claim 26, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.
- (previously presented) A method as claimed in 3, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.
- (previously presented) A method as claimed in claim 28, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.
- (original) A method as claimed in claim 3, wherein the method further includes the administration of an additional tumor growth-restricting agent.
- (withdrawn) A method as claimed in claim 30, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).
  - 32-33. (canceled).
- (withdrawn) A method as claimed in claim 4, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
- (withdrawn) A method as claimed in claim 34, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

Atty. Dkt. No. 093397-0401

36. (previously presented) A method as claimed in claim 4, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.

- (previously presented) A method as claimed in claim 36, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.
- (original) A method as claimed in claim 4, wherein the method further includes the administration of an additional tumor growth-restricting agent.
- (withdrawn) A method as claimed in claim 38, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).
  - 40-55. (canceled).

[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]